October 24, 2017 09:51 AM EDT
R&D

In an up­date, Gilead spot­lights top-line hits amid a mixed set of PhII da­ta for its $600M NASH drug

John Carroll

Editor & Founder

Six months af­ter putting out some stel­lar ear­ly-stage da­ta from a study of its NASH drug GS-0976, Gilead has come back with the full …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

Gilead plans to skip from Phase 1 to Phase 3 with once-year­ly HIV pre­ven­tion drug

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times